Results 121 to 130 of about 13,777 (259)

Machine learning‐assisted clone selection for intensified cell culture processes

open access: yesBiotechnology Progress, EarlyView.
Abstract Intensified fed‐batch processes are becoming increasingly prevalent among biomanufacturers due to their superior space–time yields relative to traditional, non‐intensified fed‐batch processes. However, the shift towards intensified manufacturing has unexpectedly made optimal clone selection more challenging.
Nicolas Wolnick   +6 more
wiley   +1 more source

Discharge Remote Monitoring Systems for Glycemic Management After Hospital Discharge

open access: yesChronic Diseases and Translational Medicine, EarlyView.
Heat map of median number of telehealth interactions by subgroup and theme. Major themes identified included intervention after remote monitoring alerts (e.g., “Team reached out to participant and instructed participant to treat hypo.”), insulin dose adjustments (e.g., “Participant reported that prednisone dose is increasing … Called to discuss insulin
Nirali Shah   +14 more
wiley   +1 more source

A Mononuclear Scenario for the Copper‐Catalyzed Monooxygenation of Phenolic Substrates

open access: yesChemistry – A European Journal, EarlyView.
ABSTRACT Whereas a dinuclear pathway applies to the monooxygenation of phenols by the type 3 copper enzyme tyrosinase, a mononuclear pathway has been identified for the same reaction in corresponding small‐molecule systems. DFT calculations of five copper model complexes reveal that the latter mechanism is energetically feasible, identifying all ...
Alexander Koch   +3 more
wiley   +1 more source

Phosphorescence of Heavy, T‐Shaped Pnictogen Trisamides in Solution at Room Temperature in the Near‐Infrared II Region

open access: yesChemistry – A European Journal, EarlyView.
The unique photophysical properties of heavy T‐shaped Sb and Bi trisamides are reported. A ligand‐to‐pnictogen charge‐transfer excitation from a redox‐active NNN pincer to a vacant pnictogen p‐orbital populates a triplet state that emits in the highly desirable NIR‐II region, with lifetimes up to the µs range.
Katharina L. Deuter   +4 more
wiley   +1 more source

Discontinuing Long‐Term Denosumab in Treating Fragile Bone: Why, for Whom, and How?

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Discontinuation of denosumab (Dmab) may be necessary due to adverse events or an unfavorable long‐term risk–benefit profile. However, accumulating evidence demonstrates pronounced rebound phenomena after withdrawal, most notably a marked increase in multiple vertebral fractures, and, in some reports, elevated mortality.
Ko‐Hsiu Lu   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy